J Korean Med Sci.  2016 Dec;31(12):1937-1942. 10.3346/jkms.2016.31.12.1937.

Antibodies against Hepatitis A and Hepatitis B Virus in Intravenous Immunoglobulin Products

• Lee S
• Kim HW
• Kim KH

• KMID: 2355622
• DOI: http://doi.org/10.3346/jkms.2016.31.12.1937

Abstract

The worldwide seroprevalence of hepatitis A virus (HAV) and hepatitis B virus (HBV) has changed over the last two decades, indicating a declining incidence of HAV and HBV infections. Therefore, vaccinations against HAV and HBV are recommended for unimmunized people before traveling to an endemic area. Unfortunately, primary antibody deficiency (PAD) patients can only obtain humoral immunity through intravenous immunoglobulin G (IVIG) replacement and not from vaccination because of a defect in antibody production. However, few studies have analyzed the titers of antibodies against HAV or HBV in IVIG products. In this study, the titers of anti-HAV and anti-HBs antibodies were measured in nineteen lots of IVIG products from five manufacturers from three countries (A, B from Korea; C, D from Japan; and E from the USA), and trough titers in plasma were estimated. Concentrations of anti-HAV antibody ranged from 1,888-8,927 mIU/mL and estimated trough titers exceeded the minimal protective value in all evaluated IVIG products. Concentrations of anti-HBs antibody ranged from 438-965 mIU/mL in products A and B and were 157, 123, and 1,945 mIU/mL in products C, D, and E, respectively. Estimated trough titers in products A, B, and E exceeded the minimal protective value but those in products C and D did not reach this threshold. These data demonstrated that available IVIG products generally provide sufficient antibodies against HAV and HBV to protect patients with PAD, although the trough concentrations of anti-HBs antibody in two IVIG products did not reach the minimum protective value.

Keyword

Antibody; Hepatitis A Virus; Hepatitis B Virus; Intravenous Immunoglobulin

MeSH Terms

Antibodies*
Antibody Formation
Hepatitis A Antibodies
Hepatitis A virus
Hepatitis A*
Hepatitis B virus*
Hepatitis B*
Hepatitis*
Humans
Immunity, Humoral
Immunoglobulin G
Immunoglobulins*
Immunoglobulins, Intravenous
Incidence
Japan
Korea
Plasma
Seroepidemiologic Studies
Vaccination
Antibodies
Hepatitis A Antibodies
Immunoglobulin G
Immunoglobulins
Immunoglobulins, Intravenous

Figure

• 

  Fig. 1 Expected trough levels of anti-hepatitis A virus (HAV) antibody (A) and anti-hepatitis B surface (HBs) antibody (B) in various intravenous immunoglobulin G (IVIG) products, assuming an infusion dose of 400 mg/kg. Short bars indicate the geometric mean and long bars indicate the minimum protective concentrations of anti-HAV and anti-HBs antibodies (20 mIU/mL and 10 mIU/mL, respectively). Numbers in brackets indicate different lot numbers of the same product.

Reference

1. Murphy TV, Denniston MM, Hill HA, McDonald M, Klevens MR, Elam-Evans LD, Nelson NP, Iskander J, Ward JD. Progress toward eliminating hepatitis A disease in the United States. MMWR Suppl. 2016; 65:29–41.

2. Ogholikhan S, Schwarz KB. Hepatitis vaccines. Vaccines (Basel). 2016; 4:E6.

3. Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010; 28:6653–6657.

4. World Health Organization. Hepatitis A [Internet]. accessed on 14 February 2016. Available at http://www.who.int/mediacentre/factsheets/fs328/en/.

5. Ciocca M. Clinical course and consequences of hepatitis A infection. Vaccine. 2000; 18:Suppl 1. S71–4.

6. Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014; 384:2053–2063.

7. World Health Organization. Hepatitis B [Internet]. accessed on 14 February 2016. Available at http://www.who.int/mediacentre/factsheets/fs204/en/.

8. Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect. 2004; 132:1005–1022.

9. Pedersini R, Marano C, De Moerlooze L, Chen L, Vietri J. HAV & HBV vaccination among travellers participating in the National Health and Wellness Survey in five European countries. Travel Med Infect Dis. 2016; 14:221–232.

10. Leder K, Chen LH, Wilson ME. Aggregate travel vs. single trip assessment: arguments for cumulative risk analysis. Vaccine. 2012; 30:2600–2604.

11. Steffen R, Behrens RH, Hill DR, Greenaway C, Leder K. Vaccine-preventable travel health risks: what is the evidence--what are the gaps? J Travel Med. 2015; 22:1–12.

12. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000; 13:602–614.

13. Joanna G, Slawomir Z, Barbara R, Barbara R. Does the proper intravenous immunoglobulin substitution in primary immunodeficiency protect against HBV infections?: a description of a case series. Med Microbiol Immunol (Berl). 2008; 197:325–328.

14. Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009; 22:396–414.

15. Soler-Palacín P, Gasó-Gago I, Fernández-Polo A, Martín-Nalda A, Oliveras M, Martinez-Cutillas J, Figueras C. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies. J Clin Immunol. 2014; 34:1015–1017.

16. Aguilar C, Malphettes M, Donadieu J, Chandesris O, Coignard-Biehler H, Catherinot E, Pellier I, Stephan JL, Le Moing V, Barlogis V, et al. Prevention of infections during primary immunodeficiency. Clin Infect Dis. 2014; 59:1462–1470.

17. Albin S, Cunningham-Rundles C. An update on the use of immunoglobulin for the treatment of immunodeficiency disorders. Immunotherapy. 2014; 6:1113–1126.

18. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008; 122:210–212.

19. Fiore AE, Wasley A, Bell BP; Advisory Committee on Immunization Practices (ACIP). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55:1–23.

20. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, Douglas JM Jr, Janssen RS, Ward JW, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006; 55:1–33.

21. Haverkate M, D’Ancona F, Giambi C, Johansen K, Lopalco PL, Cozza V, Appelgren E. VENICE project gatekeepers and contact points. Mandatory and recommended vaccination in the EU, Iceland and Norway: results of the VENICE 2010 survey on the ways of implementing national vaccination programmes. Euro Surveill. 2012; 17:20183.

22. Farcet MR, Planitzer CB, Stein O, Modrof J, Kreil TR. Hepatitis A virus antibodies in immunoglobulin preparations. J Allergy Clin Immunol. 2010; 125:198–202.

23. U.S. Food and Drug Administration, Blood Products Advisory Committee. Topic II: measles antibody levels in U.S. immune globulin products [Internet]. accessed on 1 February 2016. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4317b1-03-TopicII.htm.

24. Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. 2010; 98:12–28.

25. Moon S, Han JH, Bae GR, Cho E, Kim B. Hepatitis A in Korea from 2011 to 2013: current epidemiologic status and regional distribution. J Korean Med Sci. 2016; 31:67–72.

26. Lee H, Cho HK, Kim JH, Kim KH. Seroepidemiology of hepatitis A in Korea: changes over the past 30 years. J Korean Med Sci. 2011; 26:791–796.

27. Lee D, Ki M, Lee A, Lee KR, Park HB, Kim CS, Yoon BY, Kim JH, Lee YS, Jeong SH. A nationwide seroprevalence of total antibody to hepatitis A virus from 2005 to 2009: age and area-adjusted prevalence rates. Korean J Hepatol. 2011; 17:44–50.

28. Kiyohara T, Sato T, Totsuka A, Miyamura T, Ito T, Yoneyama T. Shifting seroepidemiology of hepatitis A in Japan, 1973-2003. Microbiol Immunol. 2007; 51:185–191.

29. Furusyo N, Hayashi J, Sawayama Y, Kawakami Y, Kishihara Y, Kashiwagi S. The elimination of hepatitis B virus infection: changing seroepidemiology of hepatitis A and B virus infection in Okinawa, Japan over a 26-year period. Am J Trop Med Hyg. 1998; 59:693–698.

30. Klevens RM, Kruszon-Moran D, Wasley A, Gallagher K, McQuillan GM, Kuhnert W, Teshale EH, Drobeniuc J, Bell BP. Seroprevalence of hepatitis A virus antibodies in the U.S.: results from the National Health and Nutrition Examination Survey. Public Health Rep. 2011; 126:522–532.

31. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA. 2005; 294:194–201.

32. Wu CY, Wang HC, Wang KT, Yang-Chih Shih D, Lo CF, Wang DY. Analyzing titers of antibodies against bacterial and viral antigens, and bacterial toxoids in the intravenous immunoglobulins utilized in Taiwan. Biologicals. 2013; 41:88–92.

33. Daily J, Werner B, Soiffer R, Fingeroth J. IGIV: a potential role for hepatitis B prophylaxis in the bone marrow peritransplant period. Bone Marrow Transplant. 1998; 21:739–742.

34. U.S. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991; 40:1–25.

35. Kim H, Lee KS, Chang SH, Park S, Kim C, Lee CH, Kweon HJ, Chung SS. Sero-prevalence of hepatitis B virus surface antigen and antibody in high school students in Chungju-city. Korean J Epidemiol. 2002; 24:107–112.

36. Kang CI, Choi CM, Park TS, Lee DJ, Oh MD, Choe KW. Incidence and seroprevalence of hepatitis A virus infections among young Korean soldiers. J Korean Med Sci. 2007; 22:546–548.

37. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, Bell B. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010; 202:192–201.

38. Akbar SM, Onji M, Kanaoka M, Horiike N, Michitaka K, Masumoto T, Nonaka T, Kanda K, Kajino K, Kumamoto I, et al. The seroepidemiology of hepatitis A and B in a Japanese town. Asia Pac J Public Health. 1992–1993; 6:26–29.

39. Schroeder HW Jr, Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection. 2012; 40:601–611.